UK – NICE approval for Verzenios in metastatic breast cancer

The National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Verzenios (abemaciclib) in combination with an aromatase inhibitor as treatment option for locally advanced or metastatic breast cancer.

Following an improved patient access scheme for Verzenios, it is now considered cost effective by the Institute and thus has been recommended as an option for these patients, meaning that they will be able to access the drug immediately.

Verzenios is one of a new type of drug called a CDK4/6 inhibitor. These are taken with an aromatase inhibitor, a type of anti-cancer drug which blocks the production of the hormone oestrogen, preventing it from stimulating the growth of some breast cancers. CDK4/6 inhibitors work by increasing the effect of aromatase inhibitors…